Temasek leads $85M round for Chi­nese biotech aim­ing for cheap­er, faster, bet­ter CAR-T ther­a­pies

The land­mark ap­provals of CAR-T ther­a­pies have been her­ald­ed, but emerg­ing sup­ply chain hur­dles cat­alyzed by the com­plex man­u­fac­tur­ing process for the cel­lu­lar ther­a­pies have pushed mak­ers to look for ways to stream­line and quick­en the process to aug­ment prod­uct vol­umes and shore up adop­tion. Chi­na’s Gra­cell is look­ing to cap­i­tal­ize on these tech­ni­cal wob­bles, with its crop of new, low cost cell ther­a­pies, with the back­ing of sto­ried in­vestor Temasek.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN